BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tulkens PM, Van Bambeke F, Zinner SH. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clin Infect Dis 2019;68:S213-22. [PMID: 30957164 DOI: 10.1093/cid/ciy1079] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Shahzad SA, Sarfraz A, Yar M, Khan ZA, Naqvi SAR, Naz S, Khan NA, Farooq U, Batool R, Ali M. Synthesis, evaluation of thymidine phosphorylase and angiogenic inhibitory potential of ciprofloxacin analogues: Repositioning of ciprofloxacin from antibiotic to future anticancer drugs. Bioorg Chem 2020;100:103876. [PMID: 32388426 DOI: 10.1016/j.bioorg.2020.103876] [Reference Citation Analysis]
2 Al-Wahaibi LH, Amer AA, Marzouk AA, Gomaa HAM, Youssif BGM, Abdelhamid AA. Design, Synthesis, and Antibacterial Screening of Some Novel Heteroaryl-Based Ciprofloxacin Derivatives as DNA Gyrase and Topoisomerase IV Inhibitors. Pharmaceuticals (Basel) 2021;14:399. [PMID: 33922361 DOI: 10.3390/ph14050399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hernandis V, Escudero E, Marín P. A novel liquid chromatography-fluorescence method for the determination of delafloxacin in human plasma. J Sep Sci 2021. [PMID: 34839590 DOI: 10.1002/jssc.202100768] [Reference Citation Analysis]
4 Nascimento-Carvalho CM. Delafloxacin as a treatment option for community-acquired pneumonia infection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34346823 DOI: 10.1080/14656566.2021.1957098] [Reference Citation Analysis]
5 Zhao M, Lepak AJ, Marchillo K, Andes DR. In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother 2019;63:e01131-19. [PMID: 31332063 DOI: 10.1128/AAC.01131-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Scott LJ. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections. Drugs 2020;80:1247-58. [PMID: 32666425 DOI: 10.1007/s40265-020-01358-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Kocsis B, Gulyás D, Szabó D. Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics (Basel) 2021;10:1506. [PMID: 34943718 DOI: 10.3390/antibiotics10121506] [Reference Citation Analysis]
8 Terreni M, Taccani M, Pregnolato M. New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules 2021;26:2671. [PMID: 34063264 DOI: 10.3390/molecules26092671] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Rusu A, Lungu IA, Moldovan OL, Tanase C, Hancu G. Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation. Pharmaceutics 2021;13:1289. [PMID: 34452252 DOI: 10.3390/pharmaceutics13081289] [Reference Citation Analysis]
10 Liapikou A, Cilloniz C, Palomeque A, Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs 2019;24:221-31. [PMID: 31657962 DOI: 10.1080/14728214.2019.1685494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Tirupathi R, Areti S, Salim SA, Palabindala V, Jonnalagadda N. Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium. J Community Hosp Intern Med Perspect 2019;9:310-3. [PMID: 31528278 DOI: 10.1080/20009666.2019.1651482] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Holland M, Bjanes E, Nizet V, Dillon N. Bicarbonate modulates delafloxacin activity against MDR Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 2021:dkab421. [PMID: 34893834 DOI: 10.1093/jac/dkab421] [Reference Citation Analysis]
13 Lodise TP, Tillotson GS, Spargo A, Bozkaya D, Massey J. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model. Clin Drug Investig 2020;40:961-71. [PMID: 32651832 DOI: 10.1007/s40261-020-00938-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Tümmler B. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Res 2019;8:F1000 Faculty Rev-1371. [PMID: 31448090 DOI: 10.12688/f1000research.19509.1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
15 Byrd BA, Zenick B, Rocha-Granados MC, Englander HE, Hare PJ, LaGree TJ, DeMarco AM, Mok WWK. The AcrAB-TolC Efflux Pump Impacts Persistence and Resistance Development in Stationary-Phase Escherichia coli following Delafloxacin Treatment. Antimicrob Agents Chemother 2021;65:e0028121. [PMID: 34097492 DOI: 10.1128/AAC.00281-21] [Reference Citation Analysis]
16 Brown Elliott BA, Wallace RJ Jr. Comparison of In Vitro Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria. Antimicrob Agents Chemother 2021;65:e0007921. [PMID: 33846136 DOI: 10.1128/AAC.00079-21] [Reference Citation Analysis]
17 Ibrahim D, Jabbour JF, Kanj SS. Current choices of antibiotic treatment for Pseudomonas aeruginosa infections. Curr Opin Infect Dis 2020;33:464-73. [PMID: 33148986 DOI: 10.1097/QCO.0000000000000677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
18 Bork JT, Werzen A, Davé R, Morgan DJ, Talwani R, Decker B. Improving Antimicrobial Use in Adult Outpatient Clinics: the New Frontier for Antimicrobial Stewardship Programs. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00722-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]